Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease.

Katie L Thoren

Journal: Seminars in hematology 2019;55(1):41-43

PMID: 29759153

Full Text on Elsevier Science View on PubMed

Abstract

Mass spectrometry methods that can detect low levels of monoclonal immunoglobulin in serum have recently been developed. These assays are based on the principle that each immunoglobulin has a unique amino acid sequence and therefore, has a unique mass. This mass can be used as a surrogate marker in order to monitor a patient's disease over time and at low levels. Here, we explain these methods, discuss their advantages and disadvantages and how they may be used to monitor monoclonal immunoglobulins for minimal residual disease detection in multiple myeloma.

Address: Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: [email protected].

DOI: 10.1053/j.seminhematol.2018.02.008

Link outs

Free resources

Medical:

https://medlineplus.gov/multiplemyeloma.html

Other Literature Sources:

Subscription / membership required

Full Text Sources:

MeSH Terms: Antibodies, Monoclonal, Humans, Mass Spectrometry, Multiple Myeloma, Neoplasm, Residual